Telles has advised the shareholders of BlueClinical on the integration of BlueClinical into Astrum, a pan-European group recently created by Henko Capital Partners, providing high quality CRO (Clinic Research Organisation) services to the pharmaceutical, biotechnology, medical and cell technology industries, currently present in France, Germany, Spain and Portugal.
Telles was involved in all stages of the transaction, which included the reinvestment of BlueClinical’s shareholders in Astrum. This operation involved the negotiation and conclusion of several contracts in a transaction that took place in several jurisdictions. BlueClinical, which was part of the Bluepharma Group, is Portugal’s leading provider of consulting services in the clinical development of drugs and clinical trials in patients, with a particular focus on early studies.
The Telles team was led by Francisco Espregueira Mendes, partner and head of the corporate, transactional and private equity practice, with the support of Tomás Barbosa and Tomás Paiva Rosado, associates in the same practice, and the intervention of Miguel Pereira Monteiro, partner at MPM Advogados.